The employment of gefitinib, a specific EGFR inhibitor, allows blockade of the TGF-α/EGFR pathway, downregulating the activation of STAT3, Akt, and ERK, and, in combination with sorafenib, can reduce the proliferation and induce the apoptosis of HCC cells under hypoxia. The gene discussed is EGFR; the disease is hepatocellular carcinoma.